MBI for Psychological Distress, SI and NSSI Among Young Adults
Impact of Mindfulness Based Therapeutic Intervention on Psychological Distress, Suicidal Ideation and Non-Suicidal Self Injury Among Young Adults: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study assessment measures:
- Informed consent form
- Demographic questionnaire
- Screener questions form
- Assessment instruments:
- Depression Anxiety and Stress Scale (DASS-21)
- Suicide Ideation Scale (SIS)
- Alexian Brothers Urge to Self Injure Scale (ABUSI)
- Mindfulness Attention Awareness Scale
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab
-
Rawalpindi, Punjab, Pakistan, 46000
- Fatima Jinnah Women University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants aged 18-24, of any gender, who consented to participate and could comprehend English (the language of the questionnaires).
- Selected respondents from the initial survey were included based on specific criteria:
- Willingness to continue participation.
- Unmarried status.
- Pursuing education (Bachelors, Masters, or Ph.D.) , Pakistan.
- Non-hosteller and unemployed.
- Residing with both parents.
- Affirmative response to screener questions about suicidal ideation (SI) and non-suicidal self-injury (NSSI).
- High scores on psychological distress and SI scales.
Exclusion Criteria:
- Participants failing to meet inclusion criteria or falling under the following categories were excluded:
- Non-students.
- History of present or past psychiatric illness, with recent medication or treatment within the past year.
- Presence of debilitating physical diseases or disabilities. Involvement in or history of substance use.
- Long-term medication for any condition, as these factors could impact study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional Group (Receiving Mindfulness Based Intervention)
after the young adults have been randomized into interventional and control groups based on high levels of psychological distress, SI and NSSI, n=30 participants from this group would receive the mindfulness based intervention.
|
During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session.
The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management.
Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program.
In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
|
|
No Intervention: Control Group (No Intervention)
A wait list control group of n=30 randomized participants from the initial cohort would be in this group and receive no intervention, until the trial is completed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychological Distress
Time Frame: 8-12 weeks
|
This refers to the overall level of emotional suffering or discomfort experienced by individuals, often encompassing symptoms of depression, anxiety, and stress.
In this study, psychological distress serves as a primary outcome measure because it is a key variable being assessed in relation to the intervention's efficacy.
|
8-12 weeks
|
|
Suicidal Ideation
Time Frame: 8-12 weeks
|
Suicidal ideation involves thoughts or ideas about engaging in behaviors intended to end one's life.
As a primary outcome measure, assessing suicidal ideation is crucial in understanding the impact of the intervention on the participants' mental health and risk of self-harm.
|
8-12 weeks
|
|
Non-Suicidal Self-Injury (NSSI)
Time Frame: 8-12 weeks
|
NSSI refers to deliberate, self-inflicted harm to one's body without suicidal intent, such as cutting or burning oneself.
It is an essential primary outcome measure in this study because it directly relates to the intervention's effectiveness in reducing self-harming behaviors among participants.
|
8-12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Fatima Jinnah Women University
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.